CR20210559A - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Info

Publication number
CR20210559A
CR20210559A CR20210559A CR20210559A CR20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A CR 20210559 A CR20210559 A CR 20210559A
Authority
CR
Costa Rica
Prior art keywords
eye diseases
sema3a
antibodies
treat eye
sema3a antibodies
Prior art date
Application number
CR20210559A
Other languages
English (en)
Inventor
Fei Han
Juergen Prestle
Leo Thomas
Kristin Laura Bovat
Dongmei Liu
Helen Haixia Wu
Nina Zippel
Sathyadevi Venkataramani
Priyanka Gupta
Rachel Rebecca Barrett
Sanjaya Singh
Rajkumar Ganesan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210559A publication Critical patent/CR20210559A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de estos que actúan sobre semaforina 3A (Sema3A). Más específicamente, se divulgan anticuerpos anti-Sema3A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
CR20210559A 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares CR20210559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09
PCT/EP2020/062802 WO2020225400A1 (en) 2019-05-09 2020-05-08 Anti-sema3a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
CR20210559A true CR20210559A (es) 2021-12-23

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210559A CR20210559A (es) 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Country Status (27)

Country Link
US (3) US11267880B2 (es)
EP (1) EP3966239A1 (es)
JP (2) JP7314310B2 (es)
KR (1) KR20220007128A (es)
CN (1) CN113795509A (es)
AR (1) AR122266A1 (es)
AU (1) AU2020267874A1 (es)
BR (1) BR112021019854A2 (es)
CA (1) CA3137377A1 (es)
CL (1) CL2021002795A1 (es)
CO (1) CO2021014768A2 (es)
CR (1) CR20210559A (es)
DO (1) DOP2021000226A (es)
EA (1) EA202193038A1 (es)
EC (1) ECSP21082527A (es)
IL (1) IL287758A (es)
JO (1) JOP20210300A1 (es)
MA (1) MA55872A (es)
MX (1) MX2021013671A (es)
MY (1) MY206253A (es)
PE (1) PE20220287A1 (es)
PH (1) PH12021552776A1 (es)
SA (1) SA521430793B1 (es)
SG (1) SG11202110842QA (es)
TW (1) TWI836069B (es)
UA (1) UA129953C2 (es)
WO (1) WO2020225400A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267874A1 (en) 2019-05-09 2021-10-28 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
US12384843B2 (en) * 2021-03-30 2025-08-12 Bayer Aktiengesellschaft Anti-semaphorin 3A antibodies
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
JP5888728B2 (ja) * 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
US9822367B2 (en) 2013-02-21 2017-11-21 Rsem, Limited Partnership Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability
EP3189074B1 (en) * 2014-09-05 2021-01-13 RSEM, Limited Partnership Compositions and methods for treating and preventing inflammation
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
WO2017074013A1 (ko) 2015-10-27 2017-05-04 사회복지법인 삼성생명공익재단 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AU2020267874A1 (en) 2019-05-09 2021-10-28 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

Also Published As

Publication number Publication date
CL2021002795A1 (es) 2022-08-05
CA3137377A1 (en) 2020-11-12
JP2023130473A (ja) 2023-09-20
JP2022531698A (ja) 2022-07-08
CO2021014768A2 (es) 2021-11-19
CN113795509A (zh) 2021-12-14
MX2021013671A (es) 2021-12-10
US20240336674A1 (en) 2024-10-10
TW202108621A (zh) 2021-03-01
MA55872A (fr) 2022-03-16
TWI836069B (zh) 2024-03-21
SA521430793B1 (ar) 2024-03-28
PE20220287A1 (es) 2022-02-25
SG11202110842QA (en) 2021-10-28
EA202193038A1 (ru) 2022-03-30
WO2020225400A1 (en) 2020-11-12
ECSP21082527A (es) 2021-12-30
EP3966239A1 (en) 2022-03-16
KR20220007128A (ko) 2022-01-18
PH12021552776A1 (en) 2022-09-19
BR112021019854A2 (pt) 2022-02-15
JP7314310B2 (ja) 2023-07-25
JP7638332B2 (ja) 2025-03-03
US20220144929A1 (en) 2022-05-12
IL287758A (en) 2022-01-01
NZ780763A (en) 2025-09-26
JOP20210300A1 (ar) 2023-01-30
DOP2021000226A (es) 2021-12-15
AR122266A1 (es) 2022-08-31
US20200385446A1 (en) 2020-12-10
AU2020267874A1 (en) 2021-10-28
US11267880B2 (en) 2022-03-08
UA129953C2 (uk) 2025-09-24
MY206253A (en) 2024-12-05

Similar Documents

Publication Publication Date Title
ECSP21082527A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
MX2021015501A (es) Anticuerpos y metodos de uso.
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
CL2023000955A1 (es) Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombótica de la retina
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.